{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:23:30Z","timestamp":1790774610780,"version":"4.1.0"},"reference-count":107,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009045","name":"Uniwersytet Jagiello\u0144ski Collegium Medicum","doi-asserted-by":"publisher","award":["U1C\/W42\/NO\/28.23"],"award-info":[{"award-number":["U1C\/W42\/NO\/28.23"]}],"id":[{"id":"10.13039\/100009045","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009045","name":"Uniwersytet Jagiello\u0144ski Collegium Medicum","doi-asserted-by":"publisher","award":["N42\/DBS\/000337"],"award-info":[{"award-number":["N42\/DBS\/000337"]}],"id":[{"id":"10.13039\/100009045","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004281","name":"National Science Centre Poland","doi-asserted-by":"publisher","award":["UMO-2022\/45\/N\/NZ7\/01850"],"award-info":[{"award-number":["UMO-2022\/45\/N\/NZ7\/01850"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004281","name":"National Science Centre Poland","doi-asserted-by":"publisher","award":["UMO-2023\/51\/B\/NZ7\/02177"],"award-info":[{"award-number":["UMO-2023\/51\/B\/NZ7\/02177"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ejmech.2025.118026","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T17:40:37Z","timestamp":1754415637000},"page":"118026","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["The first-in-class 1,3,5-triazine-derived dual 5-HT6R\/FAAH modulators in search for potential drug against neurodegenerative diseases with cognitive impairment"],"prefix":"10.1016","volume":"298","author":[{"given":"Kinga","family":"Czarnota-\u0141ydka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Kucwaj-Brysz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Mordyl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"G\u0142uch-Lutwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadeusz","family":"Karcz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Jastrz\u0119bska-Wi\u0119sek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Partyka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"D\u0105browska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz","family":"Sata\u0142a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylwia","family":"Sudo\u0142-Ta\u0142aj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Brunetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Modesto","family":"de Candia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Purgatorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Cerini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Piemontese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Podlewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gniewomir","family":"Latacz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Starek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Weso\u0142owska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Carrieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3674-3581","authenticated-orcid":false,"given":"Jadwiga","family":"Handzlik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118026_bib1","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/alz.12328","article-title":"2021 Alzheimer's disease facts and figures","volume":"17","year":"2021","journal-title":"Alzheimer\u2019s and Dementia"},{"key":"10.1016\/j.ejmech.2025.118026_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.bpc.2021.106735","article-title":"A mechanistic survey of Alzheimer's disease","volume":"281","author":"Tang","year":"2022","journal-title":"Biophys. Chem."},{"key":"10.1016\/j.ejmech.2025.118026_bib3","first-page":"263","article-title":"The alzheimer's disease clinical spectrum: diagnosis and management","volume":"103","author":"Atri","year":"2019","journal-title":"Med. Clin."},{"key":"10.1016\/j.ejmech.2025.118026_bib4","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S0006-291X(84)80190-4","article-title":"Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein","volume":"120","author":"Glenner","year":"1984","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2025.118026_bib5","article-title":"Amyloid \u03b2-based therapy for Alzheimer's disease: challenges, successes and future","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.ejmech.2025.118026_bib6","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-023-02853-3","article-title":"Tau and neuroinflammation in Alzheimer's disease: interplay mechanisms and clinical translation","volume":"20","author":"Chen","year":"2023","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.ejmech.2025.118026_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms21145035","article-title":"Seeding and growth of \u03b2-amyloid aggregates upon interaction with neuronal cell membranes","volume":"21","author":"Ruiz-Arias","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.118026_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241914499","article-title":"Anti-amyloid therapies for alzheimer's disease and the amyloid Cascade hypothesis","volume":"24","author":"Fedele","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.118026_bib9","doi-asserted-by":"crossref","DOI":"10.1038\/s44319-024-00294-4","article-title":"The controversy around anti-amyloid antibodies for treating Alzheimer's disease: the European medical agency rules against the latest anti-amyloid drugs highlights the ongoing debate about their safety and efficacy","author":"Hunter","year":"2024","journal-title":"EMBO Rep."},{"key":"10.1016\/j.ejmech.2025.118026_bib10","doi-asserted-by":"crossref","DOI":"10.1038\/d41586-024-02720-y","article-title":"Debate rages over Alzheimer's drug lecanemab as UK limits approval","author":"Kwon","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.118026_bib11","first-page":"1479","article-title":"Cholinesterase inhibitors as Alzheimer's therapeutics","volume":"20","author":"Sharma","year":"2019","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.ejmech.2025.118026_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108352","article-title":"Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease","volume":"190","author":"Marucci","year":"2021","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2025.118026_bib13","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.3390\/pharmaceutics14061117","article-title":"Therapeutic approach to Alzheimer's disease: current treatments and new perspectives","volume":"14","author":"Pardo-Moreno","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejmech.2025.118026_bib14","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2174\/1567205013666160404120542","article-title":"Butyrylcholinesterase as a diagnostic and therapeutic target for alzheimer's disease","volume":"13","author":"Darvesh","year":"2016","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.ejmech.2025.118026_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2016.00177","article-title":"One for all? Hitting multiple Alzheimer's disease targets with one drug","volume":"10","author":"Hughes","year":"2016","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.ejmech.2025.118026_bib16","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s43440-025-00715-8","article-title":"Polypharmacology: new drugs in 2023\u20132024","volume":"77","author":"Ryszkiewicz","year":"2025","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.ejmech.2025.118026_bib17","first-page":"1","article-title":"From combinations to multitarget \u2010 directed ligands : a continuum in Alzheimer \u2019 s disease polypharmacology","author":"Albertini","year":"2020","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2025.118026_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.837649","article-title":"Multi-targets: an unconventional drug development strategy for alzheimer's disease","volume":"14","author":"Gong","year":"2022","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.ejmech.2025.118026_bib19","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40263-016-0399-3","article-title":"Serotonin 5-HT6 receptor antagonists in alzheimer's disease: therapeutic rationale and current development status","volume":"31","author":"Ferrero","year":"2017","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ejmech.2025.118026_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.128275","article-title":"Chemical update on the potential for serotonin 5-HT6 and 5-HT7 receptor agents in the treatment of Alzheimer's disease","volume":"49","author":"Kucwaj-Brysz","year":"2021","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.ejmech.2025.118026_bib21","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.ejmech.2019.06.022","article-title":"Synthesis and computer-aided SAR studies for derivatives of phenoxyalkyl-1,3,5-triazine as the new potent ligands for serotonin receptors 5-HT6","volume":"178","author":"Ali","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118026_bib22","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/sj.npp.1301503","article-title":"Neuropharmacological profile of novel and selective 5-HT6 receptor agonists: WAY-181187 and WAY-208466","volume":"33","author":"Schechter","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejmech.2025.118026_bib23","series-title":"JAMA - Journal of the American Medical Association","first-page":"130","article-title":"Effect of idalopirdine as adjunct to cholinesterase inhibitors on change in cognition in patients with Alzheimer disease three randomized clinical trials","author":"Atri","year":"2018"},{"key":"10.1016\/j.ejmech.2025.118026_bib24","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-018-0368-9","article-title":"A phase 2 clinical trial of PF-05212377 (SAM-760) in subjects with mild to moderate Alzheimer's disease with existing neuropsychiatric symptoms on a stable daily dose of donepezil","volume":"10","author":"Fullerton","year":"2018","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.ejmech.2025.118026_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/biom13020309","article-title":"Progress in investigational agents targeting Serotonin-6 receptors for the treatment of brain disorders","volume":"13","author":"Nirogi","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.ejmech.2025.118026_bib26","unstructured":"Suven Life Sciences Limited, Masupirdine for the treatment of agitation in dementia of the alzheimer's type, (n.d.). https:\/\/www.clinicaltrials.gov\/study\/NCT05397639?intr=Masupirdine%20for%20the%20Treatment%20of%20Agitation%20in%20Dementia%20of%20the%20Alzheimer%27s%20Type&rank=1 (accessed May 11, 2024)."},{"key":"10.1016\/j.ejmech.2025.118026_bib27","article-title":"Bioorganic chemistry design and synthesis of new carbamates as inhibitors for fatty acid amide hydrolase and cholinesterases : molecular dynamic , in vitro and in vivo studies","volume":"109","author":"Faal","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118026_bib28","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1021\/acschemneuro.1c00699","article-title":"Effect of the MAGL\/FAAH dual inhibitor JZL-195 on streptozotocin-induced alzheimer's disease-like sporadic dementia in mice with an emphasis on A\u03b2, HSP-70, neuroinflammation, and oxidative stress","volume":"13","author":"Bajaj","year":"2022","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2025.118026_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2020.104817","article-title":"Cannabinoid-profiled agents improve cell survival via reduction of oxidative stress and inflammation, and Nrf2 activation in a toxic model combining hyperglycemia+A\u03b21-42 peptide in rat hippocampal neurons","volume":"140","author":"Elmazoglu","year":"2020","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.ejmech.2025.118026_bib30","first-page":"964","volume":"79","author":"Mart\u00edn-moreno","year":"2011","journal-title":"Cannabidiol and Other Cannabinoids Reduce Microglial Activation In Vitro and In Vivo : Relevance to Alzheimer \u2019 s Disease"},{"key":"10.1016\/j.ejmech.2025.118026_bib31","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.neuropharm.2014.06.006","article-title":"The fatty acid amide hydrolase inhibitor PF-3845 promotes neuronal survival, attenuates inflammation and improves functional recovery in mice with traumatic brain injury","volume":"85","author":"Tchantchou","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2025.118026_bib32","series-title":"Roles of the Endocannabinoid System in Learning and Memory","first-page":"201","author":"Marsicano","year":"2009"},{"key":"10.1016\/j.ejmech.2025.118026_bib33","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3390\/cells11030471","article-title":"Polypharmacological approaches for CNS diseases : focus on endocannabinoid degradation inhibition","volume":"11","author":"Papa","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2025.118026_bib34","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.mcn.2013.06.004","article-title":"Role of the cannabinoid system in the transit of beta-amyloid across the blood\u2013brain barrier","volume":"56","author":"Bachmeier","year":"2013","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.ejmech.2025.118026_bib35","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1021\/acs.jmedchem.2c01084","article-title":"Development of N -(1-Adamantyl)benzamides as novel anti-inflammatory multitarget agents acting as dual modulators of the cannabinoid CB2 receptor and fatty acid amide hydrolase","volume":"66","author":"Intranuovo","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118026_bib36","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202100559","article-title":"Discovery of isatin\u2010based carbohydrazones as potential dual inhibitors of fatty acid amide hydrolase and monoacylglycerol lipase","volume":"17","author":"Jaiswal","year":"2022","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2025.118026_bib37","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1002\/cmdc.201500507","article-title":"The molecular basis for dual fatty acid amide hydrolase (FAAH)\/cyclooxygenase (COX) inhibition","volume":"11","author":"Palermo","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2025.118026_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e32262","article-title":"Quinolinyl-based multitarget-directed ligands with soluble epoxide hydrolase and fatty acid amide hydrolase inhibitory activities: synthetic studies and pharmacological evaluations","volume":"10","author":"Angelia","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.ejmech.2025.118026_bib39","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1021\/acs.jmedchem.6b01578","volume":"60","author":"De Simone","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118026_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116208","article-title":"Novel dual-target FAAH and TRPV1 ligands as potential pharmacotherapeutics for pain management","volume":"267","author":"Qiao","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118026_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2023.105511","article-title":"Safety, tolerability, and preliminary efficacy of SYN120, a dual 5-HT6\/5-HT2A antagonist, for the treatment of parkinson disease dementia: a randomized, controlled, proof-of-concept trial","volume":"114","author":"Fernandez","year":"2023","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.ejmech.2025.118026_bib42","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/ijnp\/pyac003","article-title":"Dual 5-HT3 and 5-HT6 receptor antagonist FPPQ normalizes phencyclidine-induced disruption of brain oscillatory activity in rats","volume":"25","author":"Casta\u00f1\u00e9","year":"2022","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.ejmech.2025.118026_bib43","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ejmech.2016.05.048","article-title":"Design, synthesis, and pharmacological evaluation of multitarget-directed ligands with both serotonergic subtype 4 receptor (5-HT4R) partial agonist and 5-HT6R antagonist activities, as potential treatment of Alzheimer's disease","volume":"121","author":"Yahiaoui","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118026_bib44","doi-asserted-by":"crossref","first-page":"4543","DOI":"10.1021\/jm401895u","article-title":"Novel arylsulfonamide derivatives with 5-HT 6\/5-HT 7 receptor antagonism targeting behavioral and psychological symptoms of dementia","volume":"57","author":"Ko\u0142aczkowski","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118026_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108099","article-title":"Dual-acting agents for improving cognition and real-world function in Alzheimer's disease: focus on 5-HT6 and D3 receptors as hubs","volume":"177","author":"Millan","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2025.118026_bib46","doi-asserted-by":"crossref","DOI":"10.1021\/acschemneuro.4c00873","article-title":"Procognitive potential of neuroprotective triazine 5-HT6 receptor antagonists tested on chronic activity in vivo in rats: computer-aided insight into the role of chalcogen-differences on the pharmacological profile","author":"Jastrz\u0119bska-Wi\u0119sek","year":"2025","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2025.118026_bib47","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1021\/acs.jmedchem.3c02148","article-title":"The first-in-class Se-containing potent 5-HT6 receptor agents with a beneficial neuroprotective profile: a new hope in search for an effective Alzheimer\u2019s disease therapy","volume":"67","author":"Pyka","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118026_bib48","doi-asserted-by":"crossref","first-page":"10773","DOI":"10.3390\/ijms221910773","article-title":"The phenoxyalkyltriazine antagonists for 5-HT6 receptor with promising procognitive and pharmacokinetic properties in vivo in search for a novel therapeutic approach to dementia diseases","volume":"22","author":"Sudo\u0142","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.118026_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112529","article-title":"Chlorine substituents and linker topology as factors of 5-HT6R activity for novel highly active 1,3,5-triazine derivatives with procognitive properties in vivo","volume":"203","author":"Sudo\u0142","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118026_bib50","doi-asserted-by":"crossref","first-page":"4674","DOI":"10.1016\/j.bmcl.2011.06.096","article-title":"The discovery and development of inhibitors of fatty acid amide hydrolase","volume":"21","author":"Otrubova","year":"2011","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.ejmech.2025.118026_bib51","first-page":"823","article-title":"Aryl piperazinyl ureas as inhibitors of fatty acid amide hydrolase (FAAH) in rat, dog, and primate","volume":"3","author":"Keith","year":"2012","journal-title":"American Chemical Society Medicinal Chemistry Letters"},{"key":"10.1016\/j.ejmech.2025.118026_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114358","article-title":"Structure-based design of novel donepezil-like hybrids for a multi-target approach to the therapy of Alzheimer's disease","volume":"237","author":"Brunetti","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118026_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107895","article-title":"Rivastigmine structure-based hybrids as potential multi-target anti-alzheimer\u2019s drug candidates","volume":"153","author":"Leuci","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118026_bib54","doi-asserted-by":"crossref","first-page":"958","DOI":"10.3390\/molecules27030958","article-title":"A new series of aryloxyacetic acids endowed with multi-target activity towards peroxisome proliferator-activated receptors (PPARs), Fatty Acid Amide Hydrolase (FAAH), and Acetylcholinesterase (AChE)","volume":"27","author":"Leuci","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.118026_bib55","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ejmech.2014.06.032","article-title":"Aryl-1,3,5-triazine derivatives as histamine H4 receptor ligands","volume":"83","author":"\u0141azewska","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118026_bib56","doi-asserted-by":"crossref","first-page":"115695","DOI":"10.1016\/j.ejmech.2023.115695","article-title":"Synthesis, computational and experimental pharmacological studies for (Thio)ether-triazine 5-HT6R ligands with noticeable action on AChE\/BChE and chalcogen-dependent intrinsic activity in search for new class of drugs against Alzheimer\u2019s disease","volume":"259","author":"Czarnota-\u0141ydka","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118026_bib57","doi-asserted-by":"crossref","first-page":"5208","DOI":"10.3390\/molecules26175208","article-title":"First-in-Class isonipecotamide-based thrombin and cholinesterase dual inhibitors with potential for alzheimer disease","volume":"26","author":"Purgatorio","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.118026_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2024.117829","article-title":"Chiral pyrrolidines as multipotent agents in alzheimer and neurodegenerative diseases","volume":"110","author":"Carrieri","year":"2024","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118026_bib59","series-title":"Hallucinogens and Serotonin 5-HT2A Receptor-Mediated Signaling Pathways","first-page":"45","author":"L\u00f3pez-Gim\u00e9nez","year":"2017"},{"key":"10.1016\/j.ejmech.2025.118026_bib60","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/cpt.2282","article-title":"Discovery of nonracemic amisulpride to maximize benefit\/risk of 5\u2010HT7 and D2 receptor antagonism for the treatment of mood disorders","volume":"110","author":"Hopkins","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2025.118026_bib61","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s10020-022-00497-2","article-title":"Central nervous system effects of 5-HT7 receptors: a potential target for neurodegenerative diseases","volume":"28","author":"Quintero-Villegas","year":"2022","journal-title":"Molecular Medicine"},{"key":"10.1016\/j.ejmech.2025.118026_bib62","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1016\/j.molcel.2022.05.031","article-title":"GPCRs steer Gi and Gs selectivity via TM5-TM6 switches as revealed by structures of serotonin receptors","volume":"82","author":"Huang","year":"2022","journal-title":"Mol Cell"},{"key":"10.1016\/j.ejmech.2025.118026_bib63","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/aps.2012.55","article-title":"The essential role for aromatic cluster in the \u03b23 adrenergic receptor","volume":"33","author":"Cai","year":"2012","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejmech.2025.118026_bib64","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1016\/j.bmcl.2010.03.110","article-title":"Highly potent, non-basic 5-HT6 ligands. Site mutagenesis evidence for a second binding mode at 5-HT6 for antagonism","volume":"20","author":"Harris","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.ejmech.2025.118026_bib65","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1021\/acs.jmedchem.8b00836","article-title":"Aminergic GPCR-ligand interactions: a chemical and structural map of receptor mutation data","volume":"62","author":"Vass","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118026_bib66","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0006-8993(94)90334-4","article-title":"Protein kinase C activation inhibits glutamate-induced cytotoxicity in a neuronal cell line","volume":"652","author":"Davis","year":"1994","journal-title":"Brain Res."},{"key":"10.1016\/j.ejmech.2025.118026_bib67","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.lfs.2008.12.008","article-title":"HT22 hippocampal neuronal cell line possesses functional cholinergic properties","volume":"84","author":"Liu","year":"2009","journal-title":"Life Sci."},{"key":"10.1016\/j.ejmech.2025.118026_bib68","doi-asserted-by":"crossref","first-page":"9220","DOI":"10.1096\/fj.201900604R","article-title":"High molecular weight amyloid \u03b2 1\u201042 oligomers induce neurotoxicity via plasma membrane damage","volume":"33","author":"Yasumoto","year":"2019","journal-title":"FASEB J."},{"key":"10.1016\/j.ejmech.2025.118026_bib69","series-title":"Cannabinoid CB 2 Receptors and Fatty Acid Amide Hydrolase are Selectively Overexpressed in Neuritic Plaque-Associated Glia in Alzheimer's Disease Brains","author":"Benito","year":"2003"},{"key":"10.1016\/j.ejmech.2025.118026_bib70","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1038\/s41401-020-0385-7","article-title":"Potential application of endocannabinoid system agents in neuropsychiatric and neurodegenerative Diseases\u2014Focusing on FAAH\/MAGL inhibitors","volume":"41","author":"yu Ren","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejmech.2025.118026_bib71","doi-asserted-by":"crossref","DOI":"10.1111\/febs.17403","article-title":"Fatty-acid amide hydrolase inhibition mitigates Alzheimer's disease progression in mouse models of amyloidosis","author":"Oddi","year":"2025","journal-title":"FEBS J."},{"key":"10.1016\/j.ejmech.2025.118026_bib72","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22147711","article-title":"Fatty acid amide hydrolase (faah) inhibition modulates amyloid-beta-induced microglia polarization","volume":"22","author":"Grieco","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.118026_bib73","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.brainresbull.2022.11.008","article-title":"Interlacing the relevance of caspase activation in the onset and progression of Alzheimer's disease","volume":"192","author":"Dhage","year":"2023","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.ejmech.2025.118026_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104684","article-title":"Design and synthesis of new carbamates as inhibitors for fatty acid amide hydrolase and cholinesterases: molecular dynamic, in vitro and in vivo studies","volume":"109","author":"Maleki","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118026_bib75","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/cbdd.14175","article-title":"Role of calcium dysregulation in Alzheimer's disease and its therapeutic implications","volume":"101","author":"Joshi","year":"2023","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2025.118026_bib76","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s41583-019-0132-6","article-title":"Oxidative stress, dysfunctional glucose metabolism and alzheimer disease","volume":"20","author":"Butterfield","year":"2019","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.ejmech.2025.118026_bib77","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1006\/abio.1999.4019","article-title":"Spectrophotometric quantitation of antioxidant capacity through the formation of a phosphomolybdenum complex: specific application to the determination of vitamin E","volume":"269","author":"Prieto","year":"1999","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ejmech.2025.118026_bib78","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/5698931","article-title":"Does the interdependence between oxidative stress and inflammation explain the antioxidant paradox?","volume":"2016","author":"Biswas","year":"2016","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.ejmech.2025.118026_bib79","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.biocel.2006.07.001","article-title":"Free radicals and antioxidants in normal physiological functions and human disease","volume":"39","author":"Valko","year":"2007","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.118026_bib80","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/npp.2010.158","article-title":"Pharmacological enhancement of memory and executive functioning in laboratory animals","volume":"36","author":"Floresco","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejmech.2025.118026_bib81","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.pbb.2011.03.011","article-title":"Putative cognitive enhancers in preclinical models related to schizophrenia: the search for an elusive target","volume":"99","author":"Barak","year":"2011","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.ejmech.2025.118026_bib82","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.3390\/ijms20143420","article-title":"The 1,3,5-Triazine derivatives as innovative chemical family of 5-HT6 serotonin receptor agents with therapeutic perspectives for cognitive impairment","volume":"20","author":"Latacz","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.118026_bib83","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25074050","article-title":"Potential therapeutic targets to modulate the endocannabinoid system in alzheimer's disease","volume":"25","author":"Kanwal","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.118026_bib84","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-021-02276-y","article-title":"Potentiation of amyloid beta phagocytosis and amelioration of synaptic dysfunction upon FAAH deletion in a mouse model of Alzheimer's disease","volume":"18","author":"Ruiz-P\u00e9rez","year":"2021","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.ejmech.2025.118026_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107176","article-title":"Cannabidiol and positive effects on object recognition memory in an in vivo model of fragile X syndrome: obligatory role of hippocampal GPR55 receptors","volume":"203","author":"Manduca","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2025.118026_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2024.173943","article-title":"Discovery of novel fatty acid amide hydrolase (FAAH) inhibitors as anti-alzheimer agents via in-silico-based drug design, virtual screening, molecular docking, molecular dynamics simulation, DFT, and non-clinical studies","volume":"247","author":"Jain","year":"2025","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.ejmech.2025.118026_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117003","article-title":"Natural phenol carbamates: selective BuChE\/FAAH dual inhibitors show neuroprotection in an Alzheimer's disease mouse model","volume":"281","author":"Rong","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118026_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115756","article-title":"Hydrophobicity modulation via the substituents at positions 2 and 4 of 1,3,5-triazine to enhance therapeutic ability against Alzheimer's disease for potent serotonin 5-HT6R agents","volume":"260","author":"Sudo\u0142-Ta\u0142aj","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118026_bib89","series-title":"Relationship Between the Inhibition Constant (K1) and the Concentration of Inhibitor Which Causes 50 per Cent Inhibition (I50) of an Enzymatic Reaction","author":"Cheng","year":"1973"},{"key":"10.1016\/j.ejmech.2025.118026_bib90","doi-asserted-by":"crossref","first-page":"5208","DOI":"10.3390\/molecules26175208","article-title":"First-in-class isonipecotamide-based thrombin and cholinesterase dual inhibitors with potential for alzheimer disease","volume":"26","author":"Purgatorio","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.118026_bib91","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/cmdc.202000583","article-title":"Evaluation of water-soluble mannich base prodrugs of 2,3,4,5-Tetrahydroazepino[4,3-b]indol-1(6H)-one as multitarget-directed agents for alzheimer's disease","volume":"16","author":"Purgatorio","year":"2021","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2025.118026_bib92","series-title":"Schr\u00f6dinger Release 2024-4, Maestro","author":"Schr\u00f6dinger","year":"2024"},{"key":"10.1016\/j.ejmech.2025.118026_bib93","unstructured":"QUACPAC 1.7.0.2: OpenEye Scientific Software, Santa Fe, NM. http:\/\/www.eyesopen.com, (n.d.)."},{"key":"10.1016\/j.ejmech.2025.118026_bib94","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1758-2946-3-33","article-title":"Open babel: an open chemical toolbox","volume":"3","author":"O'Boyle","year":"2011","journal-title":"J Cheminform"},{"key":"10.1016\/j.ejmech.2025.118026_bib95","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1016\/j.molcel.2022.05.031","article-title":"GPCRs steer Gi and Gs selectivity via TM5-TM6 switches as revealed by structures of serotonin receptors","volume":"82","author":"Huang","year":"2022","journal-title":"Mol Cell"},{"key":"10.1016\/j.ejmech.2025.118026_bib96","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/j.bmcl.2011.02.052","article-title":"Identification of potent, noncovalent fatty acid amide hydrolase (FAAH) inhibitors","volume":"21","author":"Gustin","year":"2011","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.ejmech.2025.118026_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2019.06.011","article-title":"A new crystal form of human acetylcholinesterase for exploratory room-temperature crystallography studies","volume":"309","author":"Gerlits","year":"2019","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.ejmech.2025.118026_bib98","doi-asserted-by":"crossref","first-page":"4972","DOI":"10.1021\/acs.jmedchem.1c00048","article-title":"Sustainable drug discovery of multi-target-directed ligands for alzheimer's disease","volume":"64","author":"Rossi","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118026_bib99","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/nar\/28.1.235","article-title":"The protein data bank","volume":"28","author":"Berman","year":"2000","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2025.118026_bib100","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1021\/acs.jcim.1c00203","article-title":"AutoDock vina 1.2.0: new docking methods, expanded force field, and python bindings","volume":"61","author":"Eberhardt","year":"2021","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2025.118026_bib101","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.ejmech.2025.118026_bib102","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s10822-019-00240-w","article-title":"Comparison of affinity ranking using AutoDock-GPU and MM-GBSA scores for BACE-1 inhibitors in the D3R grand challenge 4","volume":"33","author":"El Khoury","year":"2019","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.ejmech.2025.118026_bib103","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1002\/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B","article-title":"Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function","volume":"19","author":"Morris","year":"1998","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.ejmech.2025.118026_bib104","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1021\/jm2005145","article-title":"A force field with discrete displaceable waters and desolvation entropy for hydrated ligand docking","volume":"55","author":"Forli","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118026_bib105","unstructured":"Openeye Scientific Software, ROCS, 3.4.0.4, OpenEye Scientific Software, Santa Fe, NM, http:\/\/www.eyesopen.com, (n.d.)."},{"key":"10.1016\/j.ejmech.2025.118026_bib106","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24244472","article-title":"Are the hydantoin-1,3,5-triazine 5-HT6R ligands a hope to a find new procognitive and anti-obesity drug? Considerations based on primary in vivo assays and ADME-Tox profile in vitro","volume":"24","author":"Lubelska","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.118026_bib107","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2019.146375","article-title":"5-HT6 receptor agonist and antagonist improve memory impairments and hippocampal BDNF signaling alterations induced by MK-801","volume":"1722","author":"Rychtyk","year":"2019","journal-title":"Brain Res."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425007913?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425007913?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T17:51:30Z","timestamp":1769622690000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425007913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":107,"alternative-id":["S0223523425007913"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118026","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The first-in-class 1,3,5-triazine-derived dual 5-HT6R\/FAAH modulators in search for potential drug against neurodegenerative diseases with cognitive impairment","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118026"}}